Compatibility «Methylprednisolone» and «Dexamethasone»
Between «Methylprednisolone» and «Dexamethasone» found 9 dangerous and 18 negative interactions, joint admission is not recommended without consulting a doctor.
Interaction tableCompare |
Dexamethasone |
✘Methylprednisolone Analogs | |
✘Dexamethasone Analogs |
-
Interactions Methylprednisolone with Dexamethasone
-
Dangerous interactions
Since systemic GCS, when administered in high doses and/ or for an extended period of time, have an immunosuppressive effect, additive effects may be observed when using other immunosuppressants or antitumor agents. With simultaneous administration of GCS and antidiabetic drugs, it is necessary to monitor the condition of patients for deterioration of glycemic control, and with the abolition of GCS - for the development of signs of hypoglycemia. The simultaneous use of purine analogues with other drugs that cause suppression of the bone marrow or the immune system, such as other antitumor drugs or immunosuppressants, in pm GCS, can lead to additive effects. Since systemic GCS, when administered in high doses and/or for an extended period of time, have an immunosuppressive effect, additive effects may be observed when using other immunosuppressants. Since the use of bupropion is associated with a dose-dependent risk of seizures, it is recommended to take special care when using other drugs at the same time that can lower the threshold of convulsive readiness, such as systemic GCS. Since stomach ulcers and gastrointestinal bleeding have been reported in patients taking deferasirox, caution should be exercised when prescribing it with other drugs that are known to increase the risk of peptic ulcer or gastric bleeding, including GCS. With the simultaneous use of indapamide with other drugs associated with an increased risk of hypokalemia, such as systemic GCS, additive hypokalemia may occur. Mifepristone for termination of pregnancy is contraindicated in patients receiving long-term corticosteroid therapy, and in Cushing's disease or other chronic conditions - in patients who require simultaneous treatment with systemic corticosteroids in vital situations, for example, with serious diseases or immunosuppression after organ transplantation. In other situations, when GCS is used to treat non-life-threatening conditions, mifepristone may lead to a decrease in the effectiveness of GCS and exacerbation or deterioration of such conditions. -
Negative interactions
Many drugs are CYP3A4 substrates, some of them alter the metabolism of GCS by induction or inhibition of CYP3A4. In the presence of another CYP3A4 substrate, a change in the hepatic clearance of methylprednisolone may require appropriate dose adjustment of GCS. Drugs that inhibit the activity of CYP3A4, such as ketoconazole, erythromycin, clarithromycin, diltiazem and cyclosporine (see table below), usually reduce hepatic clearance and increase plasma concentrations of CYP3A substrates such as methylprednisolone. In the presence of a CYP3A4 inhibitor, a lower dose of methylprednisolone may be required to avoid side effects. Drugs that induce CYP3A4 activity, such as phenobarbital, rifampicin, carbamazepine and phenytoin (see table below) usually increase hepatic clearance and lead to a decrease in plasma concentrations of drugs that are CYP3A4 substrates. Withdrawal of CYP3A4 inhibitors or inducers may return clinical changes to their original state and require careful dose adjustment of methylprednisolone. CYP3A4 inducers may enhance the metabolism of GCS, and an increase in the dose of GCS may be required. Drugs that induce CYP3A4 activity may enhance the metabolism of GCS, so an increase in the dose of GCS may be required. CYP3A4 inducers may enhance the metabolism of GCS, so an increase in the dose of GCS may be required. Since the use of GCS can cause an increase in the concentration of glucose in the blood, it may be necessary to adjust the dosage of antidiabetic drugs. Simultaneous use of CYP3A4 inhibitors may lead to an increase in the concentration of GCS in blood plasma. CYP3A4 inhibitors can potentially lead to an increase in the concentration of GCS in blood plasma. Methylprednisolone and Dexamethasone belong to the same pharmaceutical group: Glucocorticosteroids. With the simultaneous use of non-potassium-sparing diuretics, in pm thiazide, with other drugs that increase the risk of hypokalemia, such as GCS, additive hypokalemia may occur. The combined use of altretamine with other drugs that cause suppression of the bone marrow or the immune system, such as GCS, may lead to the development of additional effects. The effects of potassium loss in GCS therapy may be enhanced with the simultaneous use of other drugs that cause potassium loss, including amphotericin B. The possibility of using other GCS, such as beclomethasone and prednisone, the concentration of which is less affected by strong CYP3A4 inhibitors, especially with prolonged use, should be considered. Patients who are simultaneously receiving immunosuppressants, such as GCS, together with micafungin, may be at additional risk of developing infection or other side effects. -
Unclear interactions
Methylprednisolone is a substrate of the cytochrome P450 system and is mainly metabolized by the CYP3A4 isoenzyme, which catalyzes the 6β-hydroxylation of steroids, the main phase of metabolism of endogenous and synthetic GCS. CYP3A4 substrates. CYP3A4 inhibitors. CYP3A4 inducers. The inductor of CYP3A4. Inducer and substrate of CYP3A4. Inhibitors and substrates of CYP3A4. Inhibitor and substrate of CYP3A4. Grapefruit juice is a CYP3A4 inhibitor.
-
Dangerous interactions
Decoding the colors of interactions and contraindications
Dangerous | — | a pronounced negative interaction or contraindication. |
Negative | — | negative interaction or side effect that may reduce effectiveness. |
Positive | — | the interaction can SOMETIMES be used as a positive (often a dose adjustment is needed), or it is an indication of the drug. |
No | — | the drugs do NOT interact, which is separately indicated in the instructions. |
Unclear | — | the system failed to pre-assess the danger. |
Video instruction
Additional information
- Kiberis checks interactions and evaluates drug compatibility online right in the instructions thanks to the latest artificial intelligence technologies. The accuracy of finding is more than 95%, the accuracy of the hazard assessment is more than 80%. The online medical service takes into account all the drug groups of the selected drugs and all their components. And since the database contains 25,000 drugs with detailed instructions, not every pharmacologist can compete with our artificial intelligence. List of popular interactions.
- Why do I need to
- Avoid dangerous prescriptions for your patients.
- Check the contraindications.
- Evaluate the safety of therapy in the treatment of children.
- See the compatibility of drugs with alcohol (enter it as a drug).
- Point the doctor to the found interaction - you may need to adjust the therapy.
- The use of information about interactions is only possible as an introduction. This information should not be used to adjust therapy without consulting a specialist.
- The article is written: artificial intelligence Kiberis
- Sources: official instructions for medicines and their active substances, as well as inter-group interactions described in medical studies and textbooks.
- Total analyzed: 169,972,605 possible combinations of drugs and their components were found 412,508 interacting combinations.
- Medicine section: Standard evidence-based medicine
- The date of the last update of the interaction database: 2024-04-11
Category - medicine